The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

The CheckMate -816 trial shows nivolumab plus platinum-doublet chemotherapy significantly improves overall survival in ...

KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...

In this interview with Dr. Maria de Miguel, we explore the transformative potential of Antibody-Drug Conjugates (ADCs) in oncology. Dr. de Miguel shares insights on Temab-A, a c-Met-targeted ADC ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...